Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance

Annals of Thoracic Surgery

Volumn 62, Issue 4, 1996, Pages 1128-1133

  Øvrum, Eivind ^a,b   Holen, Einfrid Åm ^a   Tangen, Geir ^a   Ringdal, Mari Anne L ^a  

^a Oslo Heart Center   (Norway)

^b Hjertesenteret i Oslo   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIAZEPAM; DIGITALIS; FENTANYL; HEMOGLOBIN; HEPARIN; ISOFLURANE; MIDAZOLAM; NITROUS OXIDE; PANCURONIUM BROMIDE; PROTAMINE SULFATE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; ERYTHROCYTE TRANSFUSION; EXTRACORPOREAL CIRCULATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART MUSCLE REVASCULARIZATION; HEART PERFORMANCE; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0030272031     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00490-0     Document Type: Article

References (24)

1. 1. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomate Med Dev Art Org 1983;11:161-73.
2. 2. Hsu LC. Principles of heparin-coating techniques. Perfusion 1991;6:209-19.
3. 3. Videm V, Svennevig JL, Fosse E, et al. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103:806-13.
4. 4. Fosse E, Moen O, Johnson E, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-7.
5. 5. Pekna M, Hagman L, Haldèn E, Nilsson UR, Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effect of immobilized heparin. Ann Thorac Surg 1994;58:421-4.
6. 6. Øvrum E, Fosse E, Mollnes TE, et al. Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation. Eur J Cardiothorac Surg 1996;10:54-60.
7. 7. Borowiec J, Thelin S, Bagge L, Nilsson L, Venge P, Hansson HE. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;104:642-7.
8. 8. Steinberg BM, Grossi EA, Schwartz DS, et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 1995;60:525-9.
9. 9. Von Segesser LK, Weiss BM, Pasic M, Garcia E, Turina MI. Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg 1994;58:391-8.
10. 10. Borowiec J, Thelin S, Bagge L, Hultman J, Hansson H-E. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg 1992;26:177-85.
11. 11. Øvrum E, Åm Holen E, Tangen G, et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995; 60:365-71.
12. 12. Øvrum E, Åm Holen E, Tangen G. Consistent nonpharmacologie blood conservation in primary and reoperative coronary artery bypass grafting. Eur J Cardiothorac Surg 1995;9:30-35.
13. 13. Weerwind PW, Maessen JG, van Tits LJH, et al. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 1995;110:1633-41.
14. 14. Redmond JM, Gillinov AM, Stuart RS, et al. Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg 1993;56:474-9.
15. 15. Chenoweth DE, Cooper SW, Hugh TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503.
16. 16. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57.
17. 17. Jansen PGM, Velthuis HT, Huybregts RAJM, et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 1995;110:829-34.
18. 18. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56:539-49.
19. 19. Murasko DM, Nelson BJ, Silver R, Matour D, Kaye, D. Immunologic response in an elderly population with a mean age of 85. Am Med 1986;81:612-8.
20. 20. Øvrum E, Mollnes TE, Fosse E, et al. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg 1995;110: 1623-32.
21. 21. Khuri SF, Valeri CR, Loscalzo J, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-14.
22. 22. Øvrum E, Brosstad F, Åm Holen E, Tangen G, Abdelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995;92:2579-84.
23. 23. Øvrum E, Mollnes TE, Fosse E, et al. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann Thorac Surg 1995;60:1755-61.
24. 24. Øvrum E. Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass [Letter], Ann Thorac Surg 1996;61:1038-39.